Apolipoprotein E genotypes in a neuropathological series from the consortium to establish a registry for Alzheimer's disease

Annals of Neurology

Volumn 42, Issue 3, 1997, Pages 319-325

  Welsh Bohmer, Kathleen A ^a,e   Gearing, Maria ^a,d   Saunders, Ann M ^a,b   Roses, Allen D ^a,c   Mirra, Suzanne ^c  

^a Department of Psychiatry ^*  (United States)

^b Division of Neurology   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Bryan ADRC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUROPATHOLOGY; PREDICTION; PRIORITY JOURNAL; REGISTER;

AGED; ALLELES; ALZHEIMER DISEASE; APOLIPOPROTEINS E; FEMALE; FOLLOW-UP STUDIES; GENOTYPE; HUMANS; LONGITUDINAL STUDIES; MALE; PREDICTIVE VALUE OF TESTS; REGISTRIES; SENSITIVITY AND SPECIFICITY;

EID: 0030801138     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.410420308     Document Type: Article

References (38)

1. Strittmatter WJ, Saunders AM, Schmechel D, et al. Apolipoprotein E: high avidity binding to beta amyloid and increased frequency of type 4 allele in late-onset familial Alzheimer's disease. Proc Natl Acad Sei USA 1993:90:1977-1981
2. Saunders AM, Strittmatter WJ, Schmechel D, et al. Association of apolipoprotein E allele E4 with late onset familial and sporadic Alzheimer's disease. Neurology 1993:43:1467-1472
3. Corder EH, Saunders AM, Risch NJ, et al. Protective effect of the apolipoprotein E type 2 allele for late onset Alzheimer's disease. Nat Genet 1994;7:180-184
4. Roses AD. Apolipoprotein E alleles as risk factors in Alzheimer disease. Annu Rev Med 1996:47:387-400
5. Schneider JA, Gearing M, Robbins RS, et al. Apolipoprotein E genotype in diverse neurodegenerative disorders. Ann Neurol 1995:38:131-135
6. Gearing M, Schneider JA, Rebeck GW, et al. Alzheimer's disease with and without coexisting Parkinson's disease changes: apolipoprotein E genotype and neuropathologic correlates. Neurology 1995:45:1985-1990
7. Harrington CR, Louwagie J, Rossau R, et al. Influence of Apolipoprotein E genotype on senile dementia of the Alzheimer's and Lewy body types: significance for etiological theories of Alzheimer's disease. Am J Pathol 1994;145:1472-1484
8. Katzman R, Galasko D, Saitoh T, et al. Genetic evidence that the Lewy body variant is indeed a phenotypic variant of Alzheimer's disease. Brain Cogn 1995:28:259-265
9. Roses AD. Apolipoprotein E genotyping in the differential di-agnosis, not prediction of Alzheimer's disease. Ann Neurol 1995:38:6-14
10. Mayeux R, Schupf N. Apolipoprotein E and Alzheimer's disease: the implications of progress in molecular medicine. Am J Public Health 1995:85:1280-1284
11. Relkin NR. Apolipoprotein E genotyping in Alzheimer's disease. Lancet 1996:347:1091-1095
12. Shellenberg G, Payami H, Wijsman E, et al. Chromosome 14 and late onset familial Alzheimer's disease. Am J Hum Genet 1993:53:619-628
13. Sherrington R, Rogaev E, Liang Y, et al. Cloning of a gene bearing mis-sense mutations in early onset Alzheimer's disease. Nature 1995:375:754-760
14. St George-Hyslop P, Haines J, Rogaev E, et al. Genetic evidence for a novel familial Alzheimer's disease locus on chromosome 14. Nat Genet 1992;2:330-334
15. Chattier HM, Crawford F, Houlden H, et al. Early onset Alzheimer's disease caused by mutations at codon 717 of the betaamyloid precursor protein gene. Nature 1991:353:844-846
16. Goate A, Chartier HM, Mullan J, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 1991:349:704-706
17. Murrell J, Farlow M, Ghetti B, et al. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease. Science 1991:254:97-99
18. Risse SC, Raskin MA, Nochlin D, et al. Neuropathological findings in patients with clinical diagnosis of probable Alzheimer's disease. Am J Psychiatry 1990:147:168-172
19. Burns A, Luthert P, Levy R, et al. Accuracy of clinical diagnosis of Alzheimer's disease. BMJ 1990:301:1026 (Letter)
20. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of the ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology 1996:46:149-154
21. Blacker D, Albert MS, Bassett SS, et al. Reliability and validity of NINCDS-ADRDA criteria for Alzheimer's disease. Arch Neurol 1994:51:1198-1204
22. Saunders AM, Hulette C, Welsh-Bohmer KA, et al. Specificity and sensitivity of apolipoprotein E genoryping in a prospectively ascertained series of probable Alzheimer disease patients with autopsy-confirmed diagnoses. Lancet 1996:348:90-93
23. Kakulas BA, Wilton SD, Fabian VA, et al. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease in autopsy confirmed series. Lancet 1996:348:483 (Abstract)
24. Smith AD, Jobst KA, Johnston C, et al. Apolipoprotein E genotyping in the diagnosis of Alzheimer's disease. Lancet 1996:348:483-484 (Abstract)
25. Gearing M, Mirra SS, Sumi M, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part X. Neuropathology confirmation of the clinical diagnosis of Alzheimer's disease. Neurology 1995:45:461-466
26. Morris J, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. Neurology 1989:39:1159-1165
27. McKhann G, Drachman D, Folstein M, et al. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA work group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984:34:939-944
28. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry of Alzheimer's disease (CERAD) Part V: a normative study of the neuropsychological battery. Neurology 1994:44:609-614
29. Hughes CP, Berg L, Danziger WL, et al. A new clinical scale for the staging of dementia. Br J Psychiatry 1982;l40:566-572
30. Katzman R, Brown T, Fuld P, et al. Validation of a short orientation-memory-concentration test of cognitive impairment. Am J Psychiatry 1983:140:734-739
31. Mirra SS, Heyman A, McKeel D, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991:41:479-486
32. De Souza AT, Hankins GR, Washington MK, et al. Frequent loss of heterozygosity on 6q at the mannose 6-phosphate/ insulin like growth factor II receptor locus in human hepatocellular tumors. Oncogene 1995:10:1725-1729
33. Mendez MF, Mastri AR, Sung JH, et al. Clinically diagnosed Alzheimer disease: neuropathologic findings in 650 cases. AIzheimer Dis Assoc Disord 1992:6:35-43
34. Welsh KA, Mirra S, Fillenbaum G, et al. Neuropsychological and neuropathological differentiation of Alzheimer's disease from other dementias: the CERAD experience. J Int Neuropsychol Soc 1996;2:12 (Abstract)
35. Nierenberg AA, Feinstein AR. How to evaluate a diagnostic marker test: lessons from the rise and fall of the dexamethasone suppression test. JAMA 1988;259:1699-1702
36. Small GW, Mazziotta JC, Collins MT, et al. Apolipoprotein E type 4 allele and cerebral glucose metabolism in relatives at risk for familial Alzheimer's disease. JAMA 1995:27:942-947
37. Reiman EM, Caselli RJ, Yun LS, et al. Preclinical evidence of Alzheimer's disease in persons homozygous for the epsilon 4 allele for apolipoprotein E. N Engl J Med 1996:334:752-758
38. Roses AD, Saunders AM. Apolipoprotein E genotyping as a diagnostic adjunct for Alzheimer disease. Int Psychogeriatr 1997 (In press)